Legal & General Group
EVFM

Legal & General Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Legal & General Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-556
Closed -$15K – 3738
2021
Q1 		$15K Sell
556
-767
-58% -$34.9K ﹤0.01% 3265
2020
Q4 		$48K Hold
1,323
– – ﹤0.01% 2818
2020
Q3 		$47K Buy
1,323
+41
+3% +$1.78K ﹤0.01% 2715
2020
Q2 		$55K Buy
1,282
+480
+60% +$32.4K ﹤0.01% 2704
2020
Q1 		$64K Sell
802
-57
-7% -$4.56K ﹤0.01% 2528
2019
Q4 		$80K Buy
859
+702
+447% +$59.2K ﹤0.01% 2666
2019
Q3 		$12K Hold
157
– – ﹤0.01% 3249
2019
Q2 		$16K Buy
+157
New +$12.2K ﹤0.01% 3274

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Legal & General Group's EVFM Position: Q2 2021 in Review

Legal & General Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 556 shares — an estimated $15K sold.

Legal & General Group first reported a position in EVFM in Q2 2019 and held it in 8 quarters. The position peaked at $80K in Q4 2019. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

  • Legal & General Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 556 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $15K.
  • Legal & General Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Legal & General Group's Evofem Biosciences, Inc. Common Stock position peaked at $80K in Q4 2019.
  • 81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.